Compare EPRT & ORKA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EPRT | ORKA |
|---|---|---|
| Founded | 2016 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.9B | 7.1B |
| IPO Year | 2018 | 1997 |
| Metric | EPRT | ORKA |
|---|---|---|
| Price | $30.03 | $91.72 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 12 | 12 |
| Target Price | $36.79 | ★ $92.50 |
| AVG Volume (30 Days) | ★ 1.1M | 761.4K |
| Earning Date | 04-22-2026 | 05-13-2026 |
| Dividend Yield | ★ 3.98% | N/A |
| EPS Growth | ★ 11.30 | N/A |
| EPS | ★ 0.62 | N/A |
| Revenue | ★ $561,219,000.00 | N/A |
| Revenue This Year | $17.12 | N/A |
| Revenue Next Year | $16.27 | N/A |
| P/E Ratio | $48.39 | ★ N/A |
| Revenue Growth | ★ 24.82 | N/A |
| 52 Week Low | $28.95 | $14.67 |
| 52 Week High | $34.73 | $115.52 |
| Indicator | EPRT | ORKA |
|---|---|---|
| Relative Strength Index (RSI) | 36.90 | 40.35 |
| Support Level | $29.31 | $82.34 |
| Resistance Level | $31.49 | $95.02 |
| Average True Range (ATR) | 0.40 | 5.35 |
| MACD | -0.08 | -2.60 |
| Stochastic Oscillator | 6.57 | 20.19 |
Essential Properties Realty Trust Inc is a real estate investment trust. It is an internally managed real estate company acquires, owns and manages single-tenant properties that are net leased on a long-term basis to middle-market companies operating service-oriented or experience-based businesses. The Company generally invests in and leases freestanding, single-tenant commercial real estate facilities where a tenant services its customers and conducts activities that are essential to the generation of the tenant's sales and profits.
Oruka Therapeutics Inc a clinical-stage biopharmaceutical company focused on developing novel monoclonal antibody therapeutics for psoriasis (PsO) and other inflammatory and immunology (I&I) indications. Its programs are to treat and potentially modify disease by targeting mechanisms with efficacy and safety involved in disease pathology and the activity of pathogenic tissue-resident memory T cells (TRMs). Its program, ORKA-001, is designed to target the p19 subunit of interleukin-23 (IL-23p19) for the treatment of PsO. Its co-lead program, ORKA-002, is designed to target interleukin-17A and interleukin-17F (IL-17A/F) for the treatment of PsO, hidradenitis suppurativa (HS), psoriatic arthritis (PsA), and other conditions.